Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)

Next Previous
Search
Trial Profile

A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE 5
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals

Most Recent Events

  • 28 Dec 2022 Results of pooled analysis (n=1554) of two studies (FUTURE 1 & FUTURE 5) assessing quantify the prevalence and extent of pre-existing radiographic damage at baseline; investigate the association of radiographic damage with swollen/tender joint counts at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab, published in the Arthritis Research and Therapy.
  • 14 Nov 2022 Results of post hoc (n=2504) pooled analysis from the FUTURE 2, 3, 4, 5 and MAXIMISE studies investigated the impact of different levels of HU, and history of gout/uric acid lowering therapy (ULT) on pts with PsA in terms of demographics, clinical characteristics, comorbidities, and clinical response to secukinumab over 1 year, presented at the ACR Convergence 2022.
  • 28 Jul 2022 Results of a post hoc analysis assessed the efficacy of secukinumab in patients with dactylitis at baseline over 2 years published in the Clinical and Experimental Rheumatology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top